Literature DB >> 21099225

Venous hypoxia: a poorly studied etiological factor of varicose veins.

C S Lim1, M S Gohel, A C Shepherd, E Paleolog, A H Davies.   

Abstract

Venous hypoxia has long been postulated as a potential cause of varicosity formation. This article aimed to review the development of this hypothesis, including evidence supporting and controversies surrounding it. Vein wall oxygenation is achieved by oxygen diffusing from luminal blood and vasa vasorum. The whole media of varicosities is oxygenated by vasa vasorum as compared to only the outer two-thirds of media of normal veins. There was no evidence that differences exist between oxygen content of blood from varicose and non-varicose veins, although the former demonstrated larger fluctuations with postural changes. Studies using cell culture and ex vivo explants demonstrated that hypoxia activated leucocytes and endothelium which released mediators regulating vein wall remodelling similar to those observed in varicosities. Venoactive drugs may improve venous oxygenation, and inhibit hypoxia activation of leucocytes and endothelium. The evidence for hypoxia as a causative factor in varicosities remains inconclusive, mainly due to heterogeneity and poor design of published in vivostudies. However, molecular studies have shown that hypoxia was able to cause inflammatory changes and vein wall remodelling similar to those observed in varicosities. Further studies are needed to improve our understanding of the role of hypoxia and help identify potential therapeutic targets.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21099225     DOI: 10.1159/000320624

Source DB:  PubMed          Journal:  J Vasc Res        ISSN: 1018-1172            Impact factor:   1.934


  9 in total

1.  Effects of cobalt chloride on phenotypes of normal human saphenous vein smooth muscle cells.

Authors:  Jing Li; Huai-Ming Wang
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Polymorphisms in inflammation-related genes and the risk of primary varicose veins in ethnic Russians.

Authors:  Alexandra Shadrina; Elena Voronina; Mariya Smetanina; Yakov Tsepilov; Kseniya Sevost'ianova; Andrey Shevela; Evgenii Seliverstov; Elena Zakharova; Evgeny Ilyukhin; Alexander Kirienko; Igor Zolotukhin; Maxim Filipenko
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

3.  Alterations in the Plasma and Red Blood Cell Properties in Patients with Varicose Vein: A Pilot Study.

Authors:  Lukasz Gwozdzinski; Anna Pieniazek; Joanna Bernasinska-Slomczewska; Pawel Hikisz; Krzysztof Gwozdzinski
Journal:  Cardiol Res Pract       Date:  2021-06-30       Impact factor: 1.866

4.  The walking-induced transient hack concept is valid & relies on a transient early-exercise hypoxemia.

Authors:  Antoine Bruneau; Mathieu Feuilloy; Corinne Dussaussoy; Frédéric Gagnadoux; Georges Leftheriotis; Pierre Abraham
Journal:  PLoS One       Date:  2013-05-03       Impact factor: 3.240

5.  Varicose veins: role of mechanotransduction of venous hypertension.

Authors:  Hussein M Atta
Journal:  Int J Vasc Med       Date:  2012-02-12

Review 6.  Immunological aspects of chronic venous disease pathogenesis.

Authors:  Ewa Grudzińska; Zenon Paweł Czuba
Journal:  Cent Eur J Immunol       Date:  2014-12-15       Impact factor: 2.085

Review 7.  Hypoxia-inducible factor as an angiogenic master switch.

Authors:  Takuya Hashimoto; Futoshi Shibasaki
Journal:  Front Pediatr       Date:  2015-04-24       Impact factor: 3.418

8.  Characterization of atherosclerotic plaques in blood vessels with low oxygenated blood and blood pressure (Pulmonary trunk): role of growth differentiation factor-15 (GDF-15).

Authors:  G A Bonaterra; N Struck; S Zuegel; A Schwarz; L Mey; H Schwarzbach; J Strelau; R Kinscherf
Journal:  BMC Cardiovasc Disord       Date:  2021-12-17       Impact factor: 2.298

Review 9.  The role of oxygen transport in atherosclerosis and vascular disease.

Authors:  John Tarbell; Marwa Mahmoud; Andrea Corti; Luis Cardoso; Colin Caro
Journal:  J R Soc Interface       Date:  2020-04-01       Impact factor: 4.118

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.